Drug Trial Radar · NCT06214052
VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
Last checked: Nov 20, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Feb 7, 2024
Primary completion
Jun 12, 2024
Study completion Jun 12, 2024
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Jan 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future.
Conditions
- HIV Infections
Interventions
VH4524184Drug
VH4524184 was administered as tablets orally at Day 1.
Matching PlaceboDrug
VH4524184 Matching Placebo was administered as tablets orally at Day 1.
Antiretroviral therapyDrug
Antiretroviral therapy was administered as available and as per investigator's recommendation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA)Time frame: At Day 10
Locations
17 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
West Hollywood, California
GSK Investigational Site
DeLand, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Bueno, Argentina
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Elche Alicante, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Murcia, Spain
GSK Investigational Site
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.